Aurora Cannabis Expands Global Medical Portfolio in Australia and New Zealand

Aurora Cannabis Expands Its Global Medical Portfolio

In a significant move that underscores its commitment to enhancing patient care, Aurora Cannabis Inc. announced the expansion of its medical cannabis portfolio in Australia and New Zealand. This initiative aims to provide patients and healthcare providers with a broader array of scientifically-backed products, reinforcing Aurora’s status as a leader in the global medical cannabis market.

A Commitment to Quality and Accessibility

The expansion, which is marked by the introduction of new products, reflects Aurora's dedication to meet the distinct needs of the healthcare community in these regions. Stanley Sack, the Interim Managing Director for MedReleaf Australia, emphasized that Australia represents one of the company’s largest international markets, making it a top priority as they grow their presence. With a focus on delivering diversified product formats, Aurora is not only responding to evolving patient demands but also enhancing the quality of care prescribers can deliver.

New Products for the Australian and New Zealand Markets

The newly launched medical cannabis products include two THC flower variants in New Zealand; Big Wave™, a hybrid with THC 26% and CBD under 1%, Night Ride™, an indica with THC 29% and CBD under 1%, along with the balanced strain Half Moon™, which has THC 9% and CBD 13%.

For the Australian market, four new resin cartridges are being introduced: Chemango™ Kush, and Cosmic Cream™, both indica strains with THC content of 780 mg/g, as well as Lunar Express™ and Soul Train Haze™, the latter being a sativa strain, also with THC levels of 780 mg/g and a negligible amount of CBD. These products are rooted in Aurora’s proprietary genetics and are manufactured in state-of-the-art facilities that comply with EU-GMP and TGA-GMP standards, ensuring the highest quality standards are maintained for patient safety.

Strategic Focus on Long-Term Growth

Aurora Cannabis has clearly outlined its strategy that emphasizes sustained investment in Australia and New Zealand. By prioritizing the introduction of premium quality products and ensuring reliable supply channels, the company aims to continue fulfilling its responsibility towards patient needs. Their commitment is reflected in their growing portfolio, which is designed to not only cater to present demands but also to adapt to future healthcare challenges.

Aurora's comprehensive approach combines high-quality cultivation practices with regulatory expertise, which has solidified their reputation as a trusted choice for both patients and prescribers globally. Given that these steps are integral to the company’s long-term growth strategy, the expansion firmly places Aurora at the forefront of the medical cannabis industry.

About Aurora Cannabis

Founded in Canada, Aurora Cannabis has a mission to improve lives through innovative medical cannabis solutions. The company serves a wide-ranging market across Canada, Europe, and Oceania with an emphasis on high-margin opportunities and a medical-first strategy. Known for brands like Aurora®, MedReleaf®, and more, it has developed a robust supply chain along with GMP-certified manufacturing facilities to serve diverse patient needs around the world. For more information, visit Aurora's official website.

With this expansion, Aurora is set to continue leading the global medical cannabis sector, ensuring that patients and healthcare professionals have access to the highest quality cannabis products designed to improve health outcomes.